Strategic Funding and Joint-Development

Our Sole Mission:

Providing Risk Capital, Expertise, Resources and
Global Reach for Accelerated Clinical Development

The SFJ Solution:

Capital

  • Fund Trials (100%)
  • Avoid Dilution
  • Execute Large Deals
  • Bridge To Readouts
  • An Abingworth & Blackstone Company

Expertise

  • Multiple Approvals
  • US / Japan / China / EU
  • Trial Design
  • Trial Execution
  • World-Class Advisors

Resources

  • Global Reach
  • Multiple Disciplines
  • Incremental Headcount
  • CRO Management
  • Full Service

Pipeline / Asset Acceleration

  • New Indications
  • Incremental Assets
  • In-Licensing / M&A Support
  • Augmented Trial Budget
  • Parallel Trials (vs. Sequential)
  • Ex-US Approvals
SFJ Late-stage Partnerships: Maximize Retained NPV
SFJ-Solution-slogan
  • Fills operational and funding gaps
  • Provides bridge to increased ex-U.S. value
  • Assumes 100% of clinical development risk
  • Augments expertise
  • Accelerates follow-on indications
  • Tailors payback to financial objectives

SFJ By The Numbers:

Total Deal
Value

$4.5 billion

Total # of
Partnerships

11

# of Oncology Partnerships

6

Year
Founded

2009

Major Market Approvals

15

“SFJ has proven to be a collaborative and transparent partner from the start of our partnership.  Their team is extremely knowledgeable, and add immense value well beyond the financial aspect.  SFJ has remained a committed partner as we have navigated the regulatory process, with a success-driven mindset.”

 

— Cedric Francois, CEO
Apellis Pharmaceuticals

Primary Investors

blackstone-logo

Over $600 Billion

Assets Under Management

Abingowth Logo

$2.5 Billion

Raised in Life Science Funds

SFJ’s Successful Collaborations

2015

Lenvatinib
Eisai
Thyroid Cancer

US Approved

China Approved

Japan Approved

EU Approved

2017

Mylotarg
Pfizer
Myeloid
Leukemia

US Approved

Japan Approved

EU Approved

2017

Inotuzumab
Pfizer
Lymphoblastic
Leukemia

US Approved

Japan Approved

EU Approved

2018

Dacomitinib
Pfizer
Lung Cancer

US Approved

China Approved

Japan Approved

EU Approved

2021

Empaveli
Apellis
PNH

US Approved

EU Filed

Have an asset to develop?

“Working with the SFJ team to design the optimal structure for Apellis was a truly collaborative effort.  Together we structured a deal that was honestly transformational for Apellis and a true success for SFJ.  They were creative, balancing their obligations with our needs and working with them was a pleasure.  I would highly recommend.

 

— Tim Sullivan, CFO
Apellis Pharmaceuticals

SFJ’s Recent Biotech Partnerships

SFJ-Partnerships-2019
Apellis Logo

APELLIS

Apellis, a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, announced a novel, risk-sharing collaboration to support the development of APL-2 in hematologic indications with SFJ Pharmaceuticals.

SFJ-Partnerships-2020
PhaseBio Logo

PHASE BIO

PhaseBio, a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, announced a financing and co-development collaboration with SFJ to support the development of PB2452, a reversal agent for the antiplatelet therapy ticagrelor.

SFJ-Partnerships-2021
Nektar Logo

NEKTAR

Nektar Therapeutics, a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cancer and auto-immune disease, announced a financing and co-development collaboration with SFJ Pharmaceuticals to support the development of Bempegaldesleukin (BEMPEG).